What's the problem? [Regulatives / Guidelines]

posted by kumarnaidu – Mumbai, India, 2017-07-11 16:43 (2858 d 14:12 ago) – Posting: # 17533
Views: 22,262

Hi all,
Recently we did pilot and pivotal (Partial reference replicate) studies for WHO and we got high variability (CV=32%). In the USFDA product specific guidance they have suggested 2x2 crossover design for this drug. Based on our prior experience can we perform reference replicate study or need to go as per guidance?:confused:

Kumar Naidu

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
119 visitors (0 registered, 119 guests [including 11 identified bots]).
Forum time: 06:56 CEST (Europe/Vienna)

Freedom is always and exclusively
freedom for the one
who thinks differently.    Rosa Luxemburg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5